The human papillomavirus (HPV) E7 oncoprotein exists as a dimer and acts by binding to many cellular factors, preventing or retargeting their function and thereby making the infected cell conducive for viral replication. Dimerization of E7 is attributed primarily to the C-terminal domain, referred to as conserved region 3 (CR3). CR3 is highly structured and is necessary for E7's transformation ability. It is also required for binding of numerous E7 cellular targets. To systematically analyze the molecular mechanisms by which HPV16 E7 CR3 contributes to carcinogenesis, we created a comprehensive panel of mutations in residues predicted to be exposed on the surface of CR3. We analyzed our novel collection of mutants, as well as mutants targeting predicted hydrophobic core residues of the dimer, for the ability to dimerize. The same set of mutants was also assessed functionally for transformation capability in a baby rat kidney cell assay in conjugation with activated ras. We show that some mutants of HPV16 E7 CR3 failed to dimerize yet were still able to transform baby rat kidney cells. Our results identify several novel E7 mutants that abrogate transformation and also indicate that E7 does not need to exist as a stable dimer in order to transform cells.More than 100 human papillomavirus (HPV) types have been described, and more are presumed to exist (16). HPVs induce papillomas in the cutaneous and mucosal epithelia, where specific HPV types often preferentially infect distinct anatomical sites. HPVs associated with lesions that can progress to carcinogenesis are classified as "high-risk" types, the most common of which is HPV16. In contrast, HPVs associated with benign warts that regress with time are termed "lowrisk" viruses (50). Persistent infection by high-risk HPVs is associated with 99.7% of all human cervical cancer cases (15), other genitourinary cancers, and an increasingly growing number of oral cancers (21).The viral E6 and E7 oncoproteins are consistently expressed in HPV-induced cancers and are necessary to maintain malignant cell growth (3,6,29,42,43). Repression of their transcription by reexpression of the viral E2 protein induces rapid growth arrest and senescence of cervical cancer cells (22,23). The HPV E7 oncoprotein binds the product of the retinoblastoma susceptibility locus (pRb) and the related family members p107 and p130 (17). These proteins function as tumor suppressors, maintaining control of the G 1 /S checkpoint of the cell cycle by binding to the E2F family of transcription factors and by recruiting transcriptional repressor complexes to the E2F-responsive genes (10, 36). Besides pRb, the E7 oncoproteins from high-risk HPV types abrogate the inhibitory activities of the cyclin-dependent kinase inhibitors p21 and p27 by directly binding these factors (19,48). E7 interacts with the pCAF acetyltransferase, the Mi2 subunit of the NuRD histone deacetylase complex, the S4 component of the 26S proteasome, the HIF-1␣ and E2F6 transcription factors, and many other important cellular protei...